The American Cancer Society says more people are surviving cancer, and a new study estimates there are 18.6 million people in the U.S. living with a history of cancer as of Jan 1. By the year 2035, ...

The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

The Turquoise Takeover that spanned New Jersey from May 5-11 shined a spotlight on lung cancer awareness. Known as Lung ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...